Bharat Biotech’s COVAXIN® Phase III data published in The Lancet
by Priya J Hyderabad, November 12, 2021: Bharat Biotech, a global leader in vaccine development and innovation, announced today that the safety and efficacy analysis data from Phase III clinical trials of COVAXIN ® is peer reviewed and published in The Lancet. The Lancet peer-review confirms the efficacy analysis which demonstrates COVAXIN ® to be effective against COVID-19. COVAXIN ® is the only COVID-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the delta variant at 65.2%. ● Efficacy analysis demonstrates COVAXIN® to be 77.8% effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group ● Efficacy analysis demonstrates COVAXIN® to be 93.4% effective against severe symptomatic COVID-19 ● Safety analysis demonstrates adverse events reported were similar to placebo, with 12% of subjects experiencing commonly known side effects and les